Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Karelle Riviere

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Biostatistics (Oxford, England)|May 12, 2016
An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect modelsMarie-Karelle Riviere, Sebastian Ueckert, France Mentré
Computer Methods and Programs in Biomedicine|December 15, 2015
dfcomb: An R-package for phase I/II trials of drug combinationsMarie-Karelle Riviere, Jacques-Henri Jourdan, Sarah Zohar
Statistics in Medicine|July 28, 2020
Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer typesJin Jin, Marie-Karelle Riviere, Xiaodong Luo, et al.
Pharmaceutical Statistics|May 16, 2014
A Bayesian dose-finding design for drug combination clinical trials based on the logistic modelMarie-Karelle Riviere, Ying Yuan, Frédéric Dubois, et al.
Journal of Biopharmaceutical Statistics|April 30, 2019
Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count dataFlorence Loingeville, Thu Thuy Nguyen, Marie-Karelle Riviere, et al.
Statistics in Medicine|July 14, 2021
Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimensEmma Gerard, Sarah Zohar, Christelle Lorenzato, et al.
Statistical Methods in Medical Research|March 19, 2016
Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomizationMarie-Karelle Riviere, Ying Yuan, Jacques-Henri Jourdan, et al.
Biometrics|February 2, 2021
Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamicsEmma Gerard, Sarah Zohar, Hoai-Thu Thai, et al.
Statistics in Medicine|February 26, 2025
A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug DevelopmentAlessandra Serra, Julia Geronimi, Sandrine Guilleminot, et al.
Pharmaceutical Statistics|April 19, 2026
Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology TrialsHelen Barnett, Melanie Guhl, Fulvio Di Stefano, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biostatistics (Oxford, England)|May 12, 2016
An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect modelsMarie-Karelle Riviere, Sebastian Ueckert, France Mentré
Computer Methods and Programs in Biomedicine|December 15, 2015
dfcomb: An R-package for phase I/II trials of drug combinationsMarie-Karelle Riviere, Jacques-Henri Jourdan, Sarah Zohar
Statistics in Medicine|July 28, 2020
Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer typesJin Jin, Marie-Karelle Riviere, Xiaodong Luo, et al.
Pharmaceutical Statistics|May 16, 2014
A Bayesian dose-finding design for drug combination clinical trials based on the logistic modelMarie-Karelle Riviere, Ying Yuan, Frédéric Dubois, et al.
Journal of Biopharmaceutical Statistics|April 30, 2019
Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count dataFlorence Loingeville, Thu Thuy Nguyen, Marie-Karelle Riviere, et al.
Statistics in Medicine|July 14, 2021
Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimensEmma Gerard, Sarah Zohar, Christelle Lorenzato, et al.
Statistical Methods in Medical Research|March 19, 2016
Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomizationMarie-Karelle Riviere, Ying Yuan, Jacques-Henri Jourdan, et al.
Biometrics|February 2, 2021
Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamicsEmma Gerard, Sarah Zohar, Hoai-Thu Thai, et al.
Statistics in Medicine|February 26, 2025
A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug DevelopmentAlessandra Serra, Julia Geronimi, Sandrine Guilleminot, et al.
Pharmaceutical Statistics|April 19, 2026
Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology TrialsHelen Barnett, Melanie Guhl, Fulvio Di Stefano, et al.
Pageof 1